What is Abionic?
Founded in 2010, Abionic is a Swiss MedTech company renowned for its pioneering work in rapid diagnostic solutions. The company's flagship product, the abioSCOPE, is a near-patient diagnostic platform designed to deliver lab-quality results from a single drop of blood within minutes. This enables critical, timely clinical decisions at the point-of-care, particularly within emergency and intensive care settings. Abionic's technology is engineered for seamless integration into existing healthcare workflows, aiming to enhance diagnostic accuracy and efficiency for healthcare professionals globally, ultimately improving patient outcomes. The company's commitment to innovation was recognized when it was awarded Swiss MedTech of the Year in 2023.
How much funding has Abionic raised?
Abionic has raised a total of $7.7M across 2 funding rounds:
Series A
$3.7M
Series B
$4M
Series A (2012): $3.7M, investors not publicly disclosed
Series B (2014): $4M led by Drexel Morgan & Co and BlueOcean Ventures SA
Key Investors in Abionic
Drexel Morgan & Co
Drexel Morgan & Co is an investment banking firm based in Radnor, Pennsylvania, likely focusing on providing capital advisory services and strategic financial backing to companies within its portfolio.
BlueOcean Ventures SA
BlueOcean Ventures SA is an investment company specializing in early-stage medical device and life science ventures, offering both capital and extensive industry expertise to support startup growth.
What's next for Abionic?
With the recent injection of major strategic capital, Abionic is poised for accelerated growth and expanded market reach. The company's focus on point-of-care diagnostics addresses a critical need in healthcare systems worldwide, particularly for conditions requiring rapid identification such as sepsis. This latest funding round, contextualized within its overall financing history, suggests Abionic is moving towards a scaling phase, likely prioritizing the expansion of its commercial operations, further research and development into new diagnostic applications, and strengthening its global distribution network. The strategic nature of the investment indicates a strong belief in Abionic's technology and its potential to disrupt traditional diagnostic paradigms.
See full Abionic company page
